Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

37.00 0.82 −2.17%
Market cap
$22.6B
P/E
29.1×
Fwd P/E
21.0×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

7 4 4 4
ROE
28.38% 17.53% 14.96% 14.00%
ROA
23.07% 9.99% 8.66% 8.30%
ROIC
35.18% 7.08% 7.05% 6.99%
Return on Tangible Assets
38.30% 59.78% 53.38% 43.83%
Average Days of Receivables
106.50 113.03 96.47 113.10
Free Cash Flow per Share
1.93 (9.79) (9.99) (10.35)
Free Cash Flow
1,188.89 (6,084.00) (6,306.00) (6,347.00)
Other line items

Show all line items

Columns are period end dates